Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It’s very positive to see approvals for cancer immunotherapy therapies for treatment in earlier multiple myeloma, previously patients had to wait until they been through at least two previous drug regimens prior to being eligible to receive cancer immunotherapies. These therapies have seen significant results in treating patients with blood cancers, though cytokine release syndrome is a major issue. This is where we think POLB 001 can be transformational for patients, healthcare systems, and Big Pharma alike.
https://x.com/PoolbegPharma/status/1779751510999752894
I would be expecting an update on Polb-001 soon seeing as we are now in the 2 Qtr of 2024..?
Not sure what's going on here but the last week has seen a continuous amount of medium size buys at the top end of the spread...is something in the air? 🤔
Hi Moniman - I've had similar thoughts. It feels like someone (or some institution) might be accumulating at the 10p mark. Certainly feels like a lot of buys without much upward movement on the price. Interesting :-)
All clear now RNS next week 2 months after CF buy 11.5p - nice 269k buy 10.35p. 14p/15p lets see who sells - holding firm for buyout the fact i come this far what good is 50% ! HVO is up 4 times from 6p at trhe moment thats the same as POLD 50p, i feel is will go alot more, serious winner here.
Good to see its holding strong north of the 10p mark !
This may seem like a silly question, but please forgive me as i am not used to small cap stock on London AIM..
When i look at the trades for today (or any day) I see lots of very small transactions moving the price?? i see lot of transactions under 1,000 pounds and a few under 10,000 pounds but nothing over 10k GBP ?
I know there is not much liquidity in this stock, but is it really this low in terms of the daily volume / value ?
Maybe Im missing something here ?
Would really appreciate any feedback on this ...
( and for the record, Im in since the beginning as was/am an open orphan shareholder )
Heading north again today, GLA
Looking good here alright. We need concrete news to maintain the upward projection though. They are keeping their cards close to the chest with an obvious Polb 001 deal in the making.
Well into the 2nd quarter now so can't be far away. Results and news together would be nice .
Add & trim super average down to 5.4p after a large punt and a few trades - next dip is an add big. A trebler here,
Maryb..
No one is in the slightest bit interest in your personal conquests, be that on Polb, Superdry or in the bedroom. I couldn't care less what your average is, and I suppose you think you know exactly when any dips are coming..If you want to brag about your gains then maybe keep it for your mates down the pub. Do you actually have anything informative to share about Poolbeg?
Mary I'd be happy with a trip back down to 8p to buy more as I am nicely in profit at this level but regret not buying more! However I do not see a reason for that to happen and the chart shows a nicely rising trajectory
I've just bought some more, happy that it's wanting to go northwards....
11p paid and significant buying in last few days...is something about to be announced? First time above 11p since Cathal amd Jeremy ploughed a chunk of cash in here a few weeks back...GLA LTH's.
Great podcast from Jeremy, learning a lot about the person as well as POLB, an hour well spent IMHO.
GLA
Listened to the podcast on my morning run. Very illuminating about JS and his motivations. Very likeable chap and can walk the walk on the science and seems well connected in the space we need to be. Has certainly been involved in DD for acquisiation and been involved in getting a company sold. Definately a bloke I could sit and have a pint with - I think a few here under estimate JS. Pharma deals take time and are unpredictable. See destiny pharma as a prime example. Flavour of the.month and riding high with really good p2 data but struggling to get a decent value deal. Good product but cold space and antibiotics are really tricky to get approved and business model hard for big pharma to stand as antibiotics are designed to work and ideally not be used again as patient gets better so rpt sales rely on new patient. With Cart and bispecific antibodies the space is really hot and will form backbone of cancer therapy for a good few decades. The cart therapy is eye watering in cost even with recent economic savings as these therapies scale. Polb001 could be just the right drug at right time. Pharma investment is tough for those on board and most PI have expectations above reality. Poolbeg in some interesting spaces and I am just hoping in licensing from the ex amryt team of cleared assets that generate income don't cost us too.much dilution